Recent Updates — SYK
Stryker reported third-quarter 2026 operating results with net sales increasing 7.7% to $6.5 billion and organic net sales rising 7.7%. Reported diluted EPS decreased 11.7% to $1.96, while adjusted diluted EPS increased 10.3% to $3.52. The company repurchased $1.0 billion of common stock during the quarter and announced that its Board of Directors approved an additional $3.0 billion to its existing share repurchase program. Stryker updated its full-year 2026 guidance, expecting organic net sales growth between 6.5% and 7.0% and adjusted diluted EPS in the range of $14.80 to $14.90. The company operates as a global leader in medical technologies, offering innovative products and services in MedSurg, Neurotechnology, and Orthopaedics.
Stryker announced that Spencer Stiles will succeed Kevin Lobo as Chief Executive Officer, effective January 1, 2027. Stiles, currently President and COO, will also join the Board of Directors, prompting an increase in board size from 10 to 11 members. Lobo will transition to Executive Chair of the Board on the same date, retaining his base salary and bonus target but forfeiting eligibility for new stock awards. The company outlined Stiles's compensation package, including a $1.32 million annual base salary, a 150% bonus target, and a recommended $14.2 million long-term incentive award comprising stock options and performance stock units to be granted in February 2027. Stryker is a global leader in medical technologies offering products and services in MedSurg, Neurotechnology, and Orthopaedics.
Stryker Corporation reported second quarter 2026 operating results, announcing net sales of $6.6 billion, a 9.4% increase from the prior year period. Organic net sales grew 9.0%, driven by unit volume increases across its MedSurg and Neurotechnology ($3.6 billion) and Orthopaedics ($3.0 billion) segments. Reported diluted earnings per share rose 44.1% to $3.30, while adjusted diluted EPS increased 17.9% to $3.69. The company narrowed its full-year 2026 guidance, now expecting organic net sales growth between 8.3% and 9.3%, with adjusted net earnings per diluted share in the range of $14.95 to $15.10. Stryker operates as a global leader in medical technologies, providing innovative products and services in MedSurg, Neurotechnology, and Orthopaedics.
Stryker Corporation announced a reorganization of its organizational structure, creating a new Ortho Tech business. This new unit combines the orthopaedic instruments portfolio from the Instruments business with the Mako and enabling technologies portfolio from the Other Orthopaedics business. The company will maintain two reportable segments: MedSurg and Neurotechnology and Orthopaedics. Consequently, Stryker is recasting its consolidated financial statements for the three years ended December 31, 2025, to align with this new segment reporting; however, these updates are not a restatement of previously issued financial statements. Stryker operates in the medical technology industry, providing medical equipment and surgical instruments.